Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. COVID-19 in people with multiple sclerosis: A global data sharing initiative

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Predictors of treatment outcome in patients with paediatric onset multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reproductive history of the Danish multiple sclerosis population: A register-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Development of visual attention from age 7 to age 12 in children with familial high risk for schizophrenia or bipolar disorder

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hippocampal subfield morphology in monozygotic twins discordant for affective disorders

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A Contrast-Adaptive Method for Simultaneous Whole-Brain and Lesion Segmentation in Multiple Sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Erythropoietin (EPO) is a part of an endogenous neuroprotective system in the brain and may address pathophysiological mechanisms in progressive multiple sclerosis (MS).

OBJECTIVE: To evaluate a treatment effect of EPO on progressive MS.

METHODS: This was a single-center, randomized, double-blind, placebo-controlled phase 2 trial, in which 52 patients with secondary or primary progressive MS were allocated to treatment with recombinant EPO (48,000 IU) or placebo, administered intravenously 17 times during 24 weeks. Patients had an Expanded Disability Status Score (EDSS) from 4 to 6.5 and clinical progression without relapses in the 2 preceding years. The primary outcome was the change in a composite measure of maximum gait distance, hand dexterity, and cognition from baseline to 24 weeks.

RESULTS: A total of 50 patients completed the study. Venesection was performed often but no thromboembolic events occurred. We found no difference in the primary outcome between the EPO and the placebo group using the intention-to-treat principle (p = 0.22). None of the secondary outcomes, neither clinical nor magnetic resonance imaging (MRI) measures showed any significant differences.

CONCLUSION: This study provides class II evidence that treatment with high-dose EPO is not an effective treatment in patients with moderately advanced progressive MS.

Original languageEnglish
JournalMultiple sclerosis
Volume23
Issue number5
Pages (from-to)675-685
ISSN1352-4585
DOIs
Publication statusPublished - 1 Apr 2017

ID: 48333647